|Articles|November 15, 2002
- BioPharm International-11-01-2002
- Volume 15
- Issue 11
Outsourcing Outlook: Will CROs find opportunity in a Reinvigorated European R&D Sector?
Author(s)Jim Miller, Janet Lowenbach
by Jim Miller and Janet Lowenbach, PharmSource Information Services The EU must harness market forces that reward innovation and competitiveness to combat its current R&D drain.
Advertisement
Articles in this issue
about 23 years ago
Inside Washington: Major Changes Ahead for FDAabout 23 years ago
Bioinformatics Databases ? Questions of Copyrightabout 23 years ago
European Editor's Report ? An Industry Comes of Ageabout 23 years ago
Guest Editorial: Back to the Beginningabout 23 years ago
You Have Failed . . . A Case Study in Warning Letter Remediationabout 23 years ago
Survival Guide to FDA Inspections: Part 3, Responding to ObservationsNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Formulation Strategies, Tech Advances, Challenges, and Considerations in Novel Drug Delivery
2
BioPharm Weekly News Roundup—Week of Nov. 24, 2025
3
Op-Ed: Why the US Must Move Beyond Its mRNA Monoculture
4
What a $2 Billion Maryland Expansion Means for the Future of Biologics Production
5
